tiprankstipranks
Advertisement
Advertisement
RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial
PremiumCompany AnnouncementsRASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial
17d ago
EMA accelerates assessment of Revolution Medicines daraxonrasib
Premium
The Fly
EMA accelerates assessment of Revolution Medicines daraxonrasib
18d ago
Revolution Medicines price target raised to $215 from $185 at Mizuho
Premium
The Fly
Revolution Medicines price target raised to $215 from $185 at Mizuho
19d ago
Revolution Medicines Announces R&D Leadership Transition and Governance Votes
PremiumCompany AnnouncementsRevolution Medicines Announces R&D Leadership Transition and Governance Votes
1M ago
Revolution Medicines Earns Buy Rating on Strong PDAC Execution, First-Mover Advantage, and Daraxonrasib-Driven Growth Potential
Premium
Ratings
Revolution Medicines Earns Buy Rating on Strong PDAC Execution, First-Mover Advantage, and Daraxonrasib-Driven Growth Potential
2M ago
Revolution Medicines: RAS Combination Data and Phase III Plans Reinforce Pipeline Upside; Buy Rating and $175 Price Target Reiterated
Premium
Ratings
Revolution Medicines: RAS Combination Data and Phase III Plans Reinforce Pipeline Upside; Buy Rating and $175 Price Target Reiterated
2M ago
Revolution Medicines price target raised to $182 from $165 at RBC Capital
PremiumThe FlyRevolution Medicines price target raised to $182 from $165 at RBC Capital
2M ago
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
Premium
The Fly
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
2M ago
Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright
Premium
The Fly
Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100